Clinical Trials Logo

Nodular Basal Cell Carcinoma clinical trials

View clinical trials related to Nodular Basal Cell Carcinoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT05157763 Recruiting - Clinical trials for Superficial Basal Cell Carcinoma

A Study to Evaluate the Safety and Efficacy of EscharEx (EX-02) in the Treatment of Basal Cell Carcinoma

Start date: June 30, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This study will be a multicenter, prospective, open label, one-arm study intended to assess the Safety and Efficacy of EscharEx (EX-02) in the treatment of Basal Cell Carcinoma. In patients with one primary superficial or nodular basal cell carcinoma lesion with a diameter of 5-10mm (Histologically confirmed BCC) located on the trunk or upper extremities (not including the hands), with well-defined borders and no previous radiation therapy.

NCT ID: NCT04744935 Recruiting - Clinical trials for Basal Cell Carcinoma

Optical Coherence Tomography Guided Laser Treatment of Basal Cell Carcinoma

Start date: January 13, 2021
Phase: N/A
Study type: Interventional

Optical coherence tomography guided laser treatment of basal cell carcinoma

NCT ID: NCT04552990 Active, not recruiting - Clinical trials for Basal Cell Carcinoma

Use of Jet-injection in Photodynamic Therapy for Basal Cell Carcinoma

Start date: September 9, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to find out whether injecting ALA into the skin with a jet-injection device and activating the drug with light is a safe treatment that causes few or mild side effects in people with basal cell carcinoma.

NCT ID: NCT04470726 Completed - Clinical trials for Superficial Basal Cell Carcinoma

Safety and Efficacy of AIV001 on Low Risk Basal Cell Carcinoma

Start date: August 18, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

To evaluate safety and efficacy of AIV001 treatment on low-risk basal cell carcinoma.

NCT ID: NCT02270645 Completed - Clinical trials for Superficial Basal Cell Carcinoma

Randomized Pilot Study of Treatment for BCC Using the Multiplex 595/1064 nm Laser

BCC
Start date: October 2014
Phase: N/A
Study type: Interventional

Laser therapy for basal cell carcinoma may be a superior option for patients who do not wish to or cannot tolerate other treatment modalities such as topical chemotherapeutics or surgery. In this pilot study, we will preliminarily assess the efficacy and safety of the 595/1064 nm Multiplex laser when treating superficial and nodular basal cell carcinomas less than 1.5 cm in size. This is an unblinded study in which patients will be randomized to either a treatment arm or a control arm. Patients in the treatment arm will receive three treatments with the 595/1064 nm multiplex laser spaced four weeks apart. The control group will visit the clinic with the same schedule as the treatment group for monitoring of the lesion. All patients will return one month after last treatment session or clinical visit, for evaluation of clinical and histological clearance.

NCT ID: NCT02242929 Active, not recruiting - Clinical trials for Nodular Basal Cell Carcinoma

Surgery Versus Combined Treatment With Curettage and Imiquimod for Nodular Basal Cell Carcinoma

SCIN
Start date: January 2016
Phase: Phase 3
Study type: Interventional

Basal cell carcinoma (BCC) is a slow-growing, locally invasive malignant epidermal skin tumour. It is the most common malignant disease in Caucasians, representing approximately 80% of all cases of skin cancer and is therefore an important health problem. In the Netherlands incidence rates are 165 for men and 157 for women per 100.000 person-years, and these rates are rising with 3-10% every year. A simplified histological classification of BCCs includes the following three subtypes: nodular, superficial and infiltrative variants, with the nodular variant being the most frequent type. Although a characteristic feature of BCCs is their low risk to metastasize, if untreated they may be locally invasive and may induce considerable functional and cosmetic morbidity. The gold standard treatment of all histological BCC subtypes is surgical excision (SE), but not all patients are eligible for surgery. In patients with multiple BCCs and older patients, surgery may lead to significant morbidity, and in some cases, it may result in disfiguring scarring. For these reasons and to reduce workload and costs in the healthcare system, there is a growing demand for alternative, non-invasive, treatments. An advantage of non-invasive treatment options is that they can be performed by other healthcare professionals, such as general practitioners and specialized nurses. For treatment of superficial BCCs (sBCC) non-invasive treatments, such as topical imiquimod (IMQ), 5-fluorouracil (5-FU) or photodynamic therapy (PDT) are already commonly used. Our group investigated the efficacy of those three therapies and found that after 3 years, BCCs treated with IMQ had a significant lower risk of recurrence, compared to the other therapies. A recent study suggests that IMQ, besides being an immune-response modifier, also directly inhibits sonic hedgehog (SHH) signalling, the most important pathway active in BCCs. This targeted effect of IMQ very likely explains the superior therapeutic effect. Treatment of nodular BCC (nBCC) with IMQ has been investigated. Without prior curettage, high efficacy rates were found, although efficacy was still slightly inferior to SE. The investigators hypothesize that the effectiveness of IMQ following prior curettage will not be inferior to SE and that the benefits will be a higher patient satisfaction and lower healthcare costs. A recently published discreet choice experiment showed that patients preferred IMQ to surgery regardless of previous experience of BCC symptoms and treatment.

NCT ID: NCT02018679 Completed - Clinical trials for Nodular Basal Cell Carcinoma

Er:YAG Ablative Fractional Laser Assisted-Photodynamic Therapy Versus Photodynamic Therapy for Basal Cell Carcinoma

Start date: March 2011
Phase: Phase 1
Study type: Interventional

Topical photodynamic therapy with methyl-aminolaevulinate (MAL-PDT) has been introduced as an alternatively attractive procedure for BCC. Er:YAG ablative fractional laser (AFL) treatment removes the stratum corneum to increase MAL uptake and may improve efficacy. However, no studies have directly compared the efficacy of Er:YAG AFL-PDT and MAL-PDT in treating nodular BCC in Asians.

NCT ID: NCT01808950 Terminated - Clinical trials for Nodular Basal Cell Carcinoma

Non-comparative Trial Exploring Efficacy and Safety of Topical Resiquimod Gel (0.06%) in Patients With Nodular Basal Cell Carcinoma (nBCC)

Start date: January 2013
Phase: Phase 1/Phase 2
Study type: Interventional

The primary objective is the observation and description of the preliminary efficacy of resiquimod gel 0.06% on a single nodular basal cell carcinoma (nBCC) in a small group of patients.